Brief: Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
08/11/2023 13:43
Nov 8 (Reuters) - Silo Pharma Inc SILO.O :
* SILO PHARMA TO INITIATE DOSE-RANGING STUDY OF NOVEL
INTRANASAL
THERAPEUTIC SPC-15 FOR THE TREATMENT OF PTSD
* SILO PHARMA INC - FINAL VALIDATION REPORT IS EXPECTED IN
2024
Source text for Eikon: ID:nGNX9SQgMX
Further company coverage: SILO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Silo Pharma
See all newsBrief: Silo Pharma - Enters Asset Purchase Agreement With Larry King On October 13, 2026 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement